105 related articles for article (PubMed ID: 38743766)
1. Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates Losatuxizumab vedotin and Depatux-M in glioblastoma models.
Jain S; Griffith JI; Porath KA; Rathi S; Le J; Pasa TI; Decker PA; Gupta SK; Hu Z; Carlson BL; Bakken K; Burgenske DM; Feldsien TM; Lefebvre DR; Vaubel RA; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN
Clin Cancer Res; 2024 May; ():. PubMed ID: 38743766
[TBL] [Abstract][Full Text] [Related]
2. Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.
Porath KA; Regan MS; Griffith JI; Jain S; Stopka SA; Burgenske DM; Bakken KK; Carlson BL; Decker PA; Vaubel RA; Dragojevic S; Mladek AC; Connors MA; Hu Z; He L; Kitange GJ; Gupta SK; Feldsien TM; Lefebvre DR; Agar NYR; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN
Neurooncol Adv; 2022; 4(1):vdac130. PubMed ID: 36071925
[TBL] [Abstract][Full Text] [Related]
3. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
[TBL] [Abstract][Full Text] [Related]
4. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
Marin BM; Porath KA; Jain S; Kim M; Conage-Pough JE; Oh JH; Miller CL; Talele S; Kitange GJ; Tian S; Burgenske DM; Mladek AC; Gupta SK; Decker PA; McMinn MH; Stopka SA; Regan MS; He L; Carlson BL; Bakken K; Burns TC; Parney IF; Giannini C; Agar NYR; Eckel-Passow JE; Cochran JR; Elmquist WF; Vaubel RA; White FM; Sarkaria JN
Neuro Oncol; 2021 Dec; 23(12):2042-2053. PubMed ID: 34050676
[TBL] [Abstract][Full Text] [Related]
6. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER
J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558
[TBL] [Abstract][Full Text] [Related]
7. Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
Gan HK; Parakh S; Lassman AB; Seow A; Lau E; Lee ST; Ameratunga M; Perchyonok Y; Cao D; Burvenich IJG; O'Keefe GJ; Rigopoulos A; Gomez E; Maag D; Scott AM
Neurooncol Adv; 2021; 3(1):vdab102. PubMed ID: 34549181
[TBL] [Abstract][Full Text] [Related]
8. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Lassman AB; Pugh SL; Wang TJC; Aldape K; Gan HK; Preusser M; Vogelbaum MA; Sulman EP; Won M; Zhang P; Moazami G; Macsai MS; Gilbert MR; Bain EE; Blot V; Ansell PJ; Samanta S; Kundu MG; Armstrong TS; Wefel JS; Seidel C; de Vos FY; Hsu S; Cardona AF; Lombardi G; Bentsion D; Peterson RA; Gedye C; Bourg V; Wick A; Curran WJ; Mehta MP
Neuro Oncol; 2023 Feb; 25(2):339-350. PubMed ID: 35849035
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Cleary JM; Calvo E; Moreno V; Juric D; Shapiro GI; Vanderwal CA; Hu B; Gifford M; Barch D; Roberts-Rapp L; Ansell PJ; Xiong H; Ocampo C; Tolcher AW
Invest New Drugs; 2020 Oct; 38(5):1483-1494. PubMed ID: 32189093
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
[TBL] [Abstract][Full Text] [Related]
12. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Van Den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; De Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V
Neuro Oncol; 2020 May; 22(5):684-693. PubMed ID: 31747009
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Bain E; Ansell PJ; Holen KD; Maag D; Reardon DA
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1209-1217. PubMed ID: 29075855
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Narita Y; Muragaki Y; Kagawa N; Asai K; Nagane M; Matsuda M; Ueki K; Kuroda J; Date I; Kobayashi H; Kumabe T; Beppu T; Kanamori M; Kasai S; Nishimura Y; Xiong H; Ocampo C; Yamada M; Mishima K
Cancer Sci; 2021 Dec; 112(12):5020-5033. PubMed ID: 34609773
[TBL] [Abstract][Full Text] [Related]
15. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety.
Wang Y; Liu L; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245171
[TBL] [Abstract][Full Text] [Related]
17. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
18. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract][Full Text] [Related]
19. Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility.
Satomaa T; Pynnönen H; Vilkman A; Kotiranta T; Pitkänen V; Heiskanen A; Herpers B; Price LS; Helin J; Saarinen J
Antibodies (Basel); 2018 Mar; 7(2):. PubMed ID: 31544867
[TBL] [Abstract][Full Text] [Related]
20. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).
Padovan M; Eoli M; Pellerino A; Rizzato S; Caserta C; Simonelli M; Michiara M; Caccese M; Anghileri E; Cerretti G; Rudà R; Zagonel V; Lombardi G
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
